Medios

Medios increased revenue in the first half of 2026 by 8.4% to €1.075bn, reaching a half‑year revenue above €1bn for the first time. Despite the revenue growth, EBITDA pre fell 5.1% to €44m and the EBITDA‑pre margin dropped to 4.1%, prompting the company to cut its profit forecast for 2026. Operating cash flow was halved to €11.2m, partly due to timing effects in tax payments. Medios acquired a 74% stake in Caelo for €9.4m and raised its revenue forecast for 2026, but expects continued margin pressure and savings from the Avanti‑Medios! program. » Więcej na de.investing.com

Medios is buying 74 percent of Caesar & Loretz GmbH (Caelo), based in Hilden; the transaction is expected to close in the fourth quarter of 2026. Caelo is projected to generate around €40 million in revenue in 2026, roughly 2% of Medios’s planned revenue, but primarily serves as a door opener for entry into the market for pharmaceutical active and auxiliary substances. Medios is likely to consider further internal or external measures to strengthen this area; Q2 figures will be published tomorrow after the profit target for 2026 was already lowered. » Więcej na finanzen.net

Medios purchases 74 percent of Caesar & Loretz (Caelo); the credit‑financed purchase price is in the upper single‑digit millions and depends on future performance. Caelo expects revenue of around €40 million for 2026 and will be fully consolidated after closing. Completion is subject to market‑standard conditions and is expected in Q4 2026; the takeover has no impact on the annual forecast. Investor reaction: Medios share initially rose by about 1 percent. » Więcej na finanzen.net